At a glance
- Originator Bayer Schering Pharma
- Class Anti-inflammatories; Antipsoriatics
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Psoriasis
Most Recent Events
- 15 Dec 2000 No-Development-Reported for Psoriasis (Topical)
- 28 Jan 1998 New profile
- 28 Jan 1998 Investigation in Psoriasis (Topical)